Literature DB >> 23924998

Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Ivelin S Georgiev1, M Gordon Joyce, Tongqing Zhou, Peter D Kwong.   

Abstract

PURPOSE OF REVIEW: The HIV-1 site of binding for the CD4 receptor has long attracted attention as a potential supersite of vulnerability to antibody-mediated neutralization. We review recent findings related to effective CD4-binding site antibodies isolated from HIV-1-infected individuals and discuss implications for immunogen design. RECENT
FINDINGS: Highly effective CD4-binding site antibodies such as antibody VRC01 have the ability to neutralize over 90% of circulating HIV-1 strains. Sequence and structural analysis of these antibodies from over half a dozen HIV-1-infected donors reveals remarkable similarity in their ontogenies and their modes of recognition, all of which involve mimicry of CD4 receptor by antibody-heavy chain. Meanwhile, other effective CD4-binding site neutralizers such as antibody CH103 have been shown to utilize a different mode of recognition, with next-generation sequencing of both virus and antibody suggesting co-evolution to drive the development of antibody-neutralization breadth.
SUMMARY: The nexus of information concerning the CD4-binding site and its recognition by human antibodies capable of effective neutralization has expanded remarkably in the last few years. Although barriers are substantial, new insights from donor-serum responses, atomic-level structures of antibody-Env complexes, and next-generation sequencing of B-cell transcripts are invigorating vaccine-design efforts to elicit effective CD4-binding site antibodies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23924998      PMCID: PMC4154626          DOI: 10.1097/COH.0b013e328363a90e

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  75 in total

1.  Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold.

Authors:  Mihai L Azoitei; Bruno E Correia; Yih-En Andrew Ban; Chris Carrico; Oleksandr Kalyuzhniy; Lei Chen; Alexandria Schroeter; Po-Ssu Huang; Jason S McLellan; Peter D Kwong; David Baker; Roland K Strong; William R Schief
Journal:  Science       Date:  2011-10-21       Impact factor: 47.728

2.  Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Authors:  Xueling Wu; Tongqing Zhou; Jiang Zhu; Baoshan Zhang; Ivelin Georgiev; Charlene Wang; Xuejun Chen; Nancy S Longo; Mark Louder; Krisha McKee; Sijy O'Dell; Stephen Perfetto; Stephen D Schmidt; Wei Shi; Lan Wu; Yongping Yang; Zhi-Yong Yang; Zhongjia Yang; Zhenhai Zhang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Melissa Simek; Dennis R Burton; Wayne C Koff; Nicole A Doria-Rose; Mark Connors; James C Mullikin; Gary J Nabel; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

3.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.

Authors:  Audray Harris; Mario J Borgnia; Dan Shi; Alberto Bartesaghi; Haifeng He; Robert Pejchal; Yun Kenneth Kang; Rafael Depetris; Andre J Marozsan; Rogier W Sanders; Per Johan Klasse; Jacqueline L S Milne; Ian A Wilson; William C Olson; John P Moore; Sriram Subramaniam
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

4.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

5.  Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Authors:  Johannes F Scheid; Hugo Mouquet; Beatrix Ueberheide; Ron Diskin; Florian Klein; Thiago Y K Oliveira; John Pietzsch; David Fenyo; Alexander Abadir; Klara Velinzon; Arlene Hurley; Sunnie Myung; Farid Boulad; Pascal Poignard; Dennis R Burton; Florencia Pereyra; David D Ho; Bruce D Walker; Michael S Seaman; Pamela J Bjorkman; Brian T Chait; Michel C Nussenzweig
Journal:  Science       Date:  2011-07-14       Impact factor: 47.728

6.  Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Authors:  Christopher Sundling; Sijy O'Dell; Iyadh Douagi; Mattias N Forsell; Andreas Mörner; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

8.  Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Authors:  Tongqing Zhou; Ivelin Georgiev; Xueling Wu; Zhi-Yong Yang; Kaifan Dai; Andrés Finzi; Young Do Kwon; Johannes F Scheid; Wei Shi; Ling Xu; Yongping Yang; Jiang Zhu; Michel C Nussenzweig; Joseph Sodroski; Lawrence Shapiro; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

9.  Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.

Authors:  Christopher Sundling; Mattias N E Forsell; Sijy O'Dell; Yu Feng; Bimal Chakrabarti; Srinivas S Rao; Karin Loré; John R Mascola; Richard T Wyatt; Iyadh Douagi; Gunilla B Karlsson Hedestam
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

10.  A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.

Authors:  Mark Melchers; Katie Matthews; Robert P de Vries; Dirk Eggink; Thijs van Montfort; Ilja Bontjer; Carolien van de Sandt; Kathryn David; Ben Berkhout; John P Moore; Rogier W Sanders
Journal:  Retrovirology       Date:  2011-06-20       Impact factor: 4.602

View more
  20 in total

1.  NFPws: a web server for delineating broadly neutralizing antibody specificities from serum HIV-1 neutralization data.

Authors:  Nagarajan Raju; Ian Setliff; Ivelin S Georgiev
Journal:  Bioinformatics       Date:  2019-09-15       Impact factor: 6.937

Review 2.  Current views on the potential for development of a HIV vaccine.

Authors:  Kristen W Cohen; Nicole Frahm
Journal:  Expert Opin Biol Ther       Date:  2017-01-23       Impact factor: 4.388

3.  Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline.

Authors:  Ivelin S Georgiev; Rebecca S Rudicell; Kevin O Saunders; Wei Shi; Tatsiana Kirys; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Zhi-Yong Yang; Gilad Ofek; Mark Connors; John R Mascola; Gary J Nabel; Peter D Kwong
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

4.  Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes.

Authors:  Eri Nakatani-Webster; Shiu-Lok Hu; William M Atkins; Carlos Enrique Catalano
Journal:  J Virol Methods       Date:  2015-09-28       Impact factor: 2.014

Review 5.  Structure-Based Vaccine Antigen Design.

Authors:  Barney S Graham; Morgan S A Gilman; Jason S McLellan
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

6.  Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.

Authors:  Saikat Banerjee; Heliang Shi; Marisa Banasik; Hojin Moon; William Lees; Yali Qin; Andrew Harley; Adrian Shepherd; Michael W Cho
Journal:  Virology       Date:  2017-02-23       Impact factor: 3.616

7.  Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.

Authors:  Annette N Ratcliff; Colin M Venner; Abayomi S Olabode; Jason Knapp; Joshua Pankrac; Iulian Derecichei; Richard M Gibson; Andrés Finzi; Yue Li; Jamie F S Mann; Eric J Arts
Journal:  J Virol       Date:  2022-07-05       Impact factor: 6.549

8.  Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.

Authors:  Francesca Sironi; Mauro Malnati; Nicola Mongelli; Paolo Cozzi; Christina Guzzo; Silvia Ghezzi; Carles Martínez-Romero; Adolfo García-Sastre; Paolo Lusso; Daniela Jabes; Priscilla Biswas
Journal:  J Transl Med       Date:  2015-04-02       Impact factor: 5.531

9.  Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Authors:  Katie A Howell; Xiangguo Qiu; Jennifer M Brannan; Christopher Bryan; Edgar Davidson; Frederick W Holtsberg; Anna Z Wec; Sergey Shulenin; Julia E Biggins; Robin Douglas; Sven G Enterlein; Hannah L Turner; Jesper Pallesen; Charles D Murin; Shihua He; Andrea Kroeker; Hong Vu; Andrew S Herbert; Marnie L Fusco; Elisabeth K Nyakatura; Jonathan R Lai; Zhen-Yong Keck; Steven K H Foung; Erica Ollmann Saphire; Larry Zeitlin; Andrew B Ward; Kartik Chandran; Benjamin J Doranz; Gary P Kobinger; John M Dye; M Javad Aman
Journal:  Cell Rep       Date:  2016-05-05       Impact factor: 9.423

10.  Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Authors:  Peter B Gilbert; Michal Juraska; Allan C deCamp; Shelly Karuna; Srilatha Edupuganti; Nyaradzo Mgodi; Deborah J Donnell; Carter Bentley; Nirupama Sista; Philip Andrew; Abby Isaacs; Yunda Huang; Lily Zhang; Edmund Capparelli; Nidhi Kochar; Jing Wang; Susan H Eshleman; Kenneth H Mayer; Craig A Magaret; John Hural; James G Kublin; Glenda Gray; David C Montefiori; Margarita M Gomez; David N Burns; Julie McElrath; Julie Ledgerwood; Barney S Graham; John R Mascola; Myron Cohen; Lawrence Corey
Journal:  Stat Commun Infect Dis       Date:  2017-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.